Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aclaris Therapeutics (ACRS)
NASDAQ:ACRS
RESEARCH TOOLSreports
Holding ACRS?
Track your performance easily
See the Price Targets and Ratings of:
ACRS Analyst Ratings
Hold
0 Buy
3 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
ACRS Stock 12 Month Forecast
Average Price Target
$2.00
▼(-9.91% Downside)
| Highest Price Target$2.00 | Average Price Target$2.00 | Lowest Price Target$2.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
BTIG
Reiterated
09/17/24
H.C. Wainwright
Reiterated
09/17/24
Leerink Partners
Reiterated
08/08/24
Jefferies
$1.5→$1
Hold
-54.95%
Downside
Downgraded
01/10/24
Aclaris Therapeutics downgraded to Hold from Buy at JefferiesAclaris Therapeutics downgraded to Hold from Buy at Jefferies
Stifel Nicolaus
$1
Hold
-54.95%
Downside
Reiterated
12/19/23
Stifel Nicolaus Keeps Their Hold Rating on Aclaris Therapeutics (ACRS)
William Blair
―
Hold
―
Downgraded
11/13/23
Aclaris Therapeutics downgraded to Market Perform at William BlairAclaris Therapeutics downgraded to Market Perform at William Blair
Piper Sandler
$2
Hold
-9.91%
Downside
Downgraded
11/13/23
Hold Rating on Aclaris Therapeutics: Unfavorable ATI-450 Trial Results and Uncertainty on Upcoming ATI-1777 Trial
Cantor Fitzgerald
―
Hold
―
Downgraded
11/13/23
Aclaris Therapeutics downgraded to Neutral from Overweight at Cantor FitzgeraldAclaris Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
ACRS Analyst Recommendation Trends
Rating
Mar 24
May 24
Jul 24
Aug 24
Sep 24
Strong Buy
1
0
0
0
0
Buy
0
0
0
0
0
Hold
7
4
4
5
5
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
8
4
4
5
5
Each month's total comprises the sum of three months' worth of ratings.
ACRS Financial Forecast
ACRS Stock Forecast FAQ
What is ACRS’s average 12-month price target, according to analysts?
Based on analyst ratings, Aclaris Therapeutics’s 12-month average price target is $2.00.
What is ACRS’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for ACRS, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ACRS a Buy, Sell or Hold?
Aclaris Therapeutics has a consensus rating of Hold which is based on 0 buy ratings, 3 hold ratings and 0 sell ratings.
What is Aclaris Therapeutics’s price target?
The average price target for Aclaris Therapeutics is $2.00. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $2.00 ,the lowest forecast is $2.00. The average price target represents -9.91% Decrease from the current price of $2.22.
The highest analyst price target is $2.00 ,the lowest forecast is $2.00. The average price target represents -9.91% Decrease from the current price of $2.22.
What do analysts say about Aclaris Therapeutics?
Aclaris Therapeutics’s analyst rating consensus is a Hold. This is based on the ratings of 3 Wall Streets Analysts.
How can I buy shares of ACRS?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.